| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 18,265 | 17,336 | 20,750 | 15,288 |
| Cost of product sales | 262 | 14* | NaN | NaN |
| Research and development | 65,263 | 64,408 | 67,908 | 62,785 |
| General and administrative | NaN | NaN | 32,839 | 25,169 |
| Selling, general and administrative | 31,555 | 39,182* | NaN | NaN |
| Total operating expenses | 97,080 | 103,604 | 100,747 | 87,954 |
| Loss from operations | -78,815 | -86,268 | -79,997 | -72,666 |
| Interest and other income, net | 5,826 | 5,686 | 6,274 | 6,935 |
| Interest expense | 336 | 346 | 393 | 391 |
| Total other income, net | 5,490 | 5,340 | 5,881 | 6,544 |
| Loss before income taxes | -73,325 | -80,928 | -74,116 | -66,122 |
| Income tax expense | 8 | 71 | NaN | NaN |
| Net loss | -73,333 | -80,999 | -74,116 | -66,122 |
| Unrealized gain on short-term investments | NaN | 260 | NaN | NaN |
| Unrealized gain (loss) on short-term investments | -1,404 | NaN | NaN | NaN |
| Comprehensive loss | -74,737 | -80,739 | NaN | NaN |
| Basic EPS | -0.83 | -0.917 | -0.85 | -0.75 |
| Diluted EPS | -0.83 | -0.917 | -0.85 | -0.75 |
| Basic Average Shares | 88,610,000 | 88,058,000 | 87,645,000 | 87,586,000 |
| Diluted Average Shares | 88,610,000 | 88,058,000 | 87,645,000 | 87,586,000 |
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)